Prophylaxis, cost and effectiveness of therapy of infections caused by gram-positive organisms in neutropenic children.
Gram-positive infections are being reported with increasing frequency in children with haematological malignancies. Staphylococcus epidermidis, once considered a non-pathogenic skin contaminant, is emerging as a major cause of severe infection. However, in infants Gram-negative septicaemias are more frequent than in older children. A teicoplanin and ceftriaxone combination was assessed for use as empirical therapy of febrile episodes in neutropenic children with acute leukaemias. Of 47 patients, fever was of unknown origin in 21, and documented in 26 with 28 strains isolated; 19 Gram-positive (all sensitive to teicoplanin) and nine Gram-negative. Within 48 h, 41 patients became afebrile and the pathogen was cleared if initially present. Mean duration of treatment was 16 days. Febrile relapse occurred in 24 patients with eight documented superinfections. The need for prophylactic cover against Gram-positive organisms at the time of intravenous catheter insertion is questionable. We studied 71 patients who were randomly allocated to receive teicoplanin when the central line was inserted and if febrile, with added ceftriaxone and amikacin (arm A) or the tri-antibiotic regimen when fever occurred (arm B). In arm A a febrile episode occurred after ten days in 34/35 patients with only one Gram-positive organism isolated. In arm B a febrile episode occurred in all 36 patients after five days and ten Gram-positive strains were isolated. Those patients in arm A also received fluconazole. Amphotericin B was administered in cases of failure or relapses in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Schaison
G S
GS
Saint-Louis Hospital, Paris, France.
Decroly
F C
FC
D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D002443:Ceftriaxone / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006020:Glycopeptides / Q000627:therapeutic use; D006094:Gram-Positive Bacteria; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000191:economics; D009503:Neutropenia / Q000150:complications* / Q000191:economics; D011897:Random Allocation; D017334:Teicoplanin
D006020:Glycopeptides; D017334:Teicoplanin; D002443:Ceftriaxone